THE MUNSTA BOARD

[SPARK]

(RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis)


BEIJING, Sept 02, 2009 /PRNewswire-Asia via COMTEX/ -- RainEarth Inc. (OTC
Bulletin Board: RNER; "the Company") announced that in the second quarter of
2009, the Xinhua News Agency publicized the creation of "Opinions of the CPC
Central Committee and the State Council on Deepening the Reform of the Medical
and Health Care System" ("Opinion").

The "Opinion" proposed practical methods to enable people to go see a doctor
more easily. Reduced cost is the short-term goal and the long-term goal is to
establish a medical coverage plan for urban and rural populations that meets
their basic medical requirements more effectively and conveniently.

The Company's Chinese subsidiary, Beijing Rain and Earth Technology Development
Corp. Ltd. ("China RainEarth") not only complied with this system of medical
reform, but will also continue improving the quality of its products while
keeping prices competitive and affordable for patients.

China RainEarth's main product, blood dialysis, is an effective measure for
patients with acute and chronic renal failure (uremia) to sustain their lives.
Currently, there are about 60,000 renal failure patients, who spend more than
RMB six billion (approximately US$882 Million) every year on blood dialysis in
China.

Currently, imported products dominate the market. Comparatively, domestic
products only have less than 2% market share. With social and economic
development as well as the improvement of healthcare services, 15 million blood
dialyzers will be sold in China by 2012 and the market size will hit RMB 1.2
billion (approximately US$176 million). At that time, the market share of
domestic products will exceed 50%.

"Our blood dialysis is up to 40% cheaper than other imported dialysis. Of course
our dialysis maintains the same high quality," said Yongfu Zhu, CEO of the
Company. "Our dialysis has been used by several hospitals and as it is
recognized by more patients and hospitals, we will see continued growth for the
Company."